Stage 4 ovarian cancer carries the lowest survival rates of any stage, with an overall five-year survival of roughly 14%, but age reshapes that number dramatically. Women diagnosed before age 45 with advanced disease have a five-year relative survival above 45%, while those diagnosed at 85 or older face a rate closer to 8%. The gap is enormous, and it is not explained by age alone. Tumor biology, overall fitness, access to aggressive treatment, and a handful of genetic factors all interact in ways that make a single survival statistic misleading for any individual patient.
The Overall Stage 4 Numbers
A large prospective study following women in the United Kingdom found that five-year survival for those diagnosed at stage IV was about 14%, compared with 87% for stage I and 26% for stage III.1PubMed Central. Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study Stage IV means the cancer has spread beyond the abdomen or into organs like the liver or lungs. The current staging system splits stage IV into two sub-categories: IVA (cancer in fluid around the lungs) and IVB (spread to distant organs like the spleen, liver parenchyma, or lymph nodes outside the abdomen). In practice, the distinction does not appear to change prognosis much. One multicenter analysis found median overall survival of 25 and 28 months for IVA and IVB respectively, with no statistically significant difference between the two.2Gynecologic Oncology. The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified? A separate study reported five-year survival of about 9% for IVA and 13% for IVB, again with no meaningful prognostic difference.3International Journal of Gynecological Cancer. Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer
These numbers represent population averages that include women across all age groups, treatment intensities, and tumor types. For someone trying to understand what stage 4 means for a specific person at a specific age, the averages are only a starting point.
How Age Changes the Picture
Age is one of the strongest predictors of survival in advanced ovarian cancer. A study examining survival differences by age in stages III and IV found that women under 45 had a five-year relative survival above 45%, while that figure dropped steadily with each passing decade, falling to just 8% for women 85 and older.4PubMed. Ovarian cancer. Survival and treatment differences by age That is roughly a sixfold difference between the youngest and oldest patients with the same stage of disease.
Long-term data from the U.S. SEER cancer registry puts this in another frame. For women aged 50 to 59 with stage III or IV tumors, ten-year relative survival was about 18%. For women aged 60 to 69 with the same stages, it was roughly 15%.5PubMed Central. Trends in Relative Survival for Ovarian Cancer From 1975 to 2011 The decade-by-decade decline continues, with women over 75 faring worst. A nationwide population-based study confirmed the pattern from a different angle: among women with distant-stage ovarian cancer, those 65 and older had a five-year cause-specific mortality of about 69%, compared with roughly 50% for women under 65.6PubMed Central. Cause-specific mortality rate of ovarian cancer in the presence of competing risks of death: a nationwide population-based cohort study
The good news, relatively speaking, is that survival has improved across all age groups over time. Estonian registry data tracking ovarian cancer over 15 years found that five-year relative survival for stage IV patients rose from about 11% in the late 1990s to roughly 16% by the late 2000s.7PubMed. Time Trends in Ovarian Cancer Survival in Estonia by Age and Stage U.S. data shows a similar pattern, with the risk of dying from stage III–IV disease in 2006 roughly half what it was in 1975 after adjusting for other factors.5PubMed Central. Trends in Relative Survival for Ovarian Cancer From 1975 to 2011 Those gains reflect advances in surgery, platinum-based chemotherapy, and more recently, targeted drugs.
Why Younger Women Tend to Survive Longer
The age gap in survival is not simply about having a “younger body” that bounces back faster. The tumors themselves tend to differ biologically. High-grade serous ovarian cancer, the most common and aggressive subtype, is the dominant type in older women. But younger women who develop this same subtype are more likely to carry mutations in the BRCA1 or BRCA2 genes. One analysis found BRCA mutation rates dropped from about half of patients under 50 to under a fifth in those aged 80 and older.8Gynecologic Oncology. Distribution and prognostic role of BRCA status in elderly ovarian cancer patients BRCA-mutated tumors, paradoxically, tend to respond better to platinum-based chemotherapy and to newer drugs called PARP inhibitors, because the mutation leaves cancer cells unable to repair their own DNA when those drugs are at work.9PubMed. Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation
A molecular study comparing high-grade serous tumors in younger and older women confirmed this pattern. Younger patients were significantly more likely to carry germline BRCA1 mutations and to show broader signs of a DNA-repair deficiency that makes tumors more vulnerable to treatment. Older women’s tumors, by contrast, were more likely to have a genetic change called CCNE1 amplification, which is associated with chemotherapy resistance.10Gynecologic Oncology. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women In short, older women’s cancers are often harder to treat at the molecular level, independent of any age-related decline in health.
Younger women are also somewhat more likely to be diagnosed with less aggressive histologic subtypes. Serous carcinoma incidence peaks in the 50-to-60 range, while other subtypes like clear cell and endometrioid do not show the same steep age-related increase.11PubMed Central. Incidence of different histologic subtype of ovarian cancer in China: a population-based cancer registry study Because stage 4 is overwhelmingly dominated by high-grade serous tumors, the histologic mix matters less at this stage. But the molecular differences within that subtype matter a lot.
Frailty Matters More Than Your Birthday
Oncologists increasingly recognize that a patient’s biological fitness predicts outcomes better than the number on her driver’s license. A study of women with advanced ovarian cancer found that those classified as frail had a median survival of about 27 months, compared with roughly 45 months for non-frail patients. Frail patients were also three times as likely to die within 90 days of surgery.12Gynecologic Oncology. Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer A systematic review and meta-analysis confirmed that highly frail ovarian cancer patients had about 61% higher risk of dying than those with low frailty, and this association held regardless of age.13PubMed Central. Frailty and long-term survival of patients with ovarian cancer: A systematic review and meta-analysis
This is practically important. A fit, active 72-year-old may have a better prognosis than a 60-year-old with diabetes, heart disease, and poor nutritional status. Frailty assessments look at things like muscle strength, walking speed, weight loss, exhaustion, and how many other medical conditions a person has. The title of one influential paper captured this well: “Functional not chronologic age.” When doctors estimate how a patient will do, the frailty score often adds more predictive power than age alone. Factors like low albumin (a blood protein reflecting nutritional status), higher creatinine (reflecting kidney function), and poor performance status all climb with age but are the real drivers of who can tolerate aggressive treatment.12Gynecologic Oncology. Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer
How Surgery and Chemotherapy Play Out by Age
The standard treatment for advanced ovarian cancer is aggressive surgical removal of as much tumor as possible, followed by platinum-based chemotherapy. How much tumor is left behind after surgery, known as residual disease, is one of the strongest predictors of survival at any age. A study of women 65 and older found that when surgeons removed all visible tumor, median overall survival was about six years for patients aged 65 to 69 and five years for those 80 and older, a difference that was not statistically significant.14Gynecologic Oncology. Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: A delicate balance requiring individualization When some tumor was left behind, however, the gap widened: median survival dropped to about 3.4 years for the youngest group versus 2.1 years for the oldest. The takeaway is that complete surgery benefits older women just as much as younger ones, but incomplete surgery hits them harder.
Perioperative complications are more common in older patients. About 38% of patients aged 75 and over experienced surgical complications in that study.14Gynecologic Oncology. Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: A delicate balance requiring individualization This is why some older or frailer patients are offered chemotherapy first, with surgery delayed or sometimes skipped entirely.
When it comes to chemotherapy itself, older women tolerate standard platinum-paclitaxel regimens better than many people expect. A German study of women 70 and older found they received virtually the full recommended dose of both drugs, and side effects were comparable to younger women, with one exception: febrile neutropenia (dangerous infections during low white blood cell counts) was more common, occurring in about 5% of older patients versus less than 1% of younger ones.15Annals of Oncology. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged ≥70 years with advanced ovarian cancer—a study by the AGO OVAR Germany Another study found that women over 70 needed slightly lower carboplatin doses but completed similar numbers of treatment cycles and reached equivalent post-treatment functional status as younger patients. Rates of severe toxicity were low in both groups.16Gynecologic Oncology. Comparison of Tolerance of Combination Carboplatin and Paclitaxel Chemotherapy by Age in Women with Ovarian Cancer
PARP Inhibitors and Age
PARP inhibitors are a class of targeted drugs that have changed the treatment landscape for ovarian cancer, especially for women whose tumors have defects in DNA repair. There has been concern that older patients might not tolerate these drugs as well or might not benefit equally. The evidence suggests the benefit is real at any age, even if side effects require closer management.
A systematic review and network meta-analysis found that all three major PARP inhibitors significantly improved progression-free survival in women 65 and older, with effect sizes broadly similar to those seen in younger patients.17PubMed Central. Efficacy and safety of PARP inhibitors in older patients with advanced ovarian cancer: a systematic review and network meta-analysis An analysis from the PAOLA-1 trial, one of the landmark studies in this field, reported that women 65 and older receiving olaparib plus bevacizumab had a median progression-free survival of about 22 months compared with roughly 17 months on placebo. The benefit was nearly identical to that seen in younger women. Rates of serious side effects were comparable too, though anemia and high blood pressure were somewhat more common in older patients.18European Journal of Cancer. Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial
Where age does seem to matter is in the rate of dose adjustments and early discontinuation. A study comparing patients above and below age 60 found that roughly 64% of older patients needed dose modifications compared with about 47% of younger patients, and older patients were more than twice as likely to stop treatment due to side effects.19PubMed Central. Efficacy and toxicity of PARP inhibitor in elderly patients with homologous recombination-deficient newly diagnosed advanced ovarian cancer: the role of dose modification Even so, progression-free survival was similar in both age groups, suggesting that starting at a lower dose or adjusting along the way does not sacrifice the drug’s effectiveness. This is reassuring for older patients and their physicians.
Conditional Survival After Five Years
One of the most psychologically meaningful statistics for someone living with stage 4 ovarian cancer is conditional survival: if you have already survived a certain number of years, what are your chances going forward? These numbers look very different from the initial prognosis, and they improve with each year a patient survives.
A study using the SEER database calculated the probability that a five-year survivor of stage IV ovarian cancer would live another ten years. For women under 65, that conditional probability was about 26%. For women 65 and older, it was roughly 29%, though the confidence intervals were wide given the small number of patients who reach this milestone.20PubMed Central. Ten-Year Conditional Probability of Survival for Patients with Ovarian Cancer: A New Metric Tailored to Long-Term Survivors For comparison, stage III five-year survivors under 65 had a 58% chance of making it to the ten-year mark. These numbers tell a different story from the bleak initial statistics: if you have already beaten the odds at five years, your future outlook improves substantially, regardless of age.
Research into long-term survivors of advanced ovarian cancer has found that younger age and low-grade histology predict long-term survival, but long-term survivors also include women with high-risk features. It is not exclusively the “favorable biology” group that lives longest.21PubMed Central. Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer Among women with stage IIIC to IV disease who survived more than eight years, roughly half had experienced at least one recurrence, but they had longer intervals between treatment and recurrence and tended to receive aggressive surgical treatment when their cancer came back. Surviving beyond eight years appeared to represent a turning point after which further relapse became less likely.22PubMed. Clinical characteristics and prognostic inflection points among long-term survivors of advanced epithelial ovarian cancer
Treatment Gaps for Older Women
One of the uncomfortable realities behind age-related survival statistics is that older women often receive less treatment. They are less likely to undergo optimal surgery, less likely to receive standard chemotherapy regimens, and significantly underrepresented in clinical trials, which means the evidence guiding their care was often generated in younger, fitter patients.23Journal of Geriatric Oncology. Ovarian cancer in the older woman A study of elderly patients with advanced ovarian cancer found that being treated by a low-volume provider and being 80 or older were both independently associated with receiving chemotherapy that did not follow established guidelines.24Gynecologic Oncology. Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer
Real-world data on newer drugs tells a related story. A study examining olaparib use outside of clinical trials found that unselected older patients made up a much larger share of real-world practice than they did in the randomized trials that got the drug approved. These real-world older patients experienced more side effects and appeared to derive less benefit than the carefully selected trial participants.25PubMed Central. Olaparib treatment in older patients with ovarian cancer: need for real-world data beyond clinical trials This does not mean the drugs do not work in older women. It means the clinical-trial population is not representative of the patients actually being treated, and we need more data from the broader population to know how to dose and manage these medications optimally.
Part of the survival gap by age is therefore a treatment gap, not just a biology gap. Some older women are undertreated relative to what they could tolerate, because of assumptions about age-related fragility that frailty assessments could challenge. Others are overtreated with regimens designed for younger bodies, leading to complications that worsen outcomes. Getting this balance right depends on individualized assessment rather than relying on age cutoffs.
Competing Causes of Death
An underappreciated wrinkle in survival statistics for older women is competing risk: the older you are, the more likely you are to die of something other than ovarian cancer. This may sound morbid, but it affects how to interpret survival data. A nationwide population-based study found that among women 65 and older with distant-stage ovarian cancer, the five-year mortality from other causes (heart disease, stroke, other cancers) was about 3%, compared with roughly 2% for women under 65.6PubMed Central. Cause-specific mortality rate of ovarian cancer in the presence of competing risks of death: a nationwide population-based cohort study At earlier stages, the difference was more dramatic: for localized ovarian cancer, about 7% of women 65 and older died of non-cancer causes within five years, versus only 1% of younger women.
For stage 4 disease, competing causes of death are a relatively minor factor because the cancer itself drives most mortality. But as treatment improves and more women survive longer, these competing risks become more relevant, particularly when deciding how aggressively to treat someone who has other serious medical conditions. A treatment that adds several months of progression-free survival may not add overall survival if the patient is also managing severe heart failure or advanced kidney disease. This is another reason that frailty and comorbidity assessments increasingly guide treatment decisions alongside staging and tumor biology.
What Long-Term Survivors Have in Common
The characteristics that predict living well beyond the five-year mark with stage 4 disease are not mysterious, even if they are not entirely within anyone’s control. Complete surgical removal of visible tumor is one of the most consistent predictors. BRCA-mutated tumors, which respond well to both platinum chemotherapy and PARP inhibitors, are another. Younger age helps, but it is partly a proxy for fitness and tumor biology. A long interval between finishing initial treatment and having the cancer come back, sometimes called the platinum-free interval, strongly predicts who will become a long-term survivor among those with advanced disease.22PubMed. Clinical characteristics and prognostic inflection points among long-term survivors of advanced epithelial ovarian cancer
One study looking at elderly patients who had all visible tumor removed found that median survival stretched to five or six years regardless of whether the patient was 65 or 80, suggesting that when surgery goes well, the age penalty shrinks considerably.14Gynecologic Oncology. Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: A delicate balance requiring individualization Access to a high-volume gynecologic oncology center, where surgeons perform these complex operations routinely, also appears to matter. Treatment by a low-volume provider was independently linked to worse guideline compliance and survival in older patients.24Gynecologic Oncology. Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer For older women facing a stage 4 diagnosis, seeking care at a specialized center may be one of the most consequential practical decisions available.